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Background/aim: In recent years, the increase in the prevalence of carbapenem-resistant Enterobacter cloacae (CREC) has been
significant and has become a global problem. The aim of this study is to characterize CREC extended spectrum β-lactamases (ESBLs)
and CREC carbapenemase genes and evaluate the risk factors for CREC infections in a university hospital in China.
Materials and methods: The identification and assessment of the antimicrobial susceptibility of CREC isolates were performed using
a VITEK-2 compact system. Clonal relatedness was investigated by pulsed-field gel electrophoresis (PFGE). β-Lactamase genes were
examined using polymerase chain reaction and nucleotide sequencing.
Results: A total of 64 CREC isolates were included in the study. The rate of CREC infections significantly increased between 2009 and
2012. Among the CREC isolates, 39 (60.9%) isolates possessed ESBL genes, and 49 (76.6%) carried carbapenemase genes; blaSHV-12 and
blaKPC-2 were the most common genes, respectively. PFGE showed that there were no obvious clonal associations between these CREC
isolates, except for 3 isolates. A univariate analysis demonstrated that prior treatment with antibiotics, intravascular catheterization,
urinary catheterization, mechanical ventilation, and parenteral nutrition were significant risk factors for CREC infections.
Conclusion: The emergence and increase of CREC infections is worrisome. Effective measures should be taken to control the spread
of CREC.
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1. Introduction
Enterobacter cloacae is an increasingly important
nosocomial pathogen and can cause a wide spectrum of
infections, including pneumonia, urinary tract infections,
wound infections, and device-related infections (1). In
recent years, the antibiograms of Enterobacter cloacae
have changed greatly, including the emergence of
carbapenem-resistant Enterobacter cloacae (CREC).
CREC poses a formidable threat to hospitalized patients
because infections with CREC are difficult to treat and are
associated with high rates of morbidity and mortality in
comparison with those caused by carbapenem-susceptible
Enterobacter cloacae (2–4). Currently, Klebsiella
pneumoniae is the most frequent species of carbapenemresistant Enterobacteriaceae (5,6). In contrast, CREC is
still unusual, and the risk factors and epidemiology of
CREC have not been systematically evaluated. Extended
spectrum β-lactamases (ESBLs) and carbapenemases are
2 types of important enzymes in Enterobacteriaceae that
can lead to resistance to different antibiotics, including
* Correspondence: cuilanyingharbin@163.com

β-lactams, fluoroquinolones, aminoglycosides, and
trimethoprim/sulfamethoxazole (7). The present study
was conducted to investigate the molecular characteristics
of ESBLs and carbapenemases and to analyze risk factors
associated with CREC infections.
2. Materials and methods
2.1. Patients and bacterial strains
A retrospective study was conducted at the First Affiliated
Hospital of Harbin Medical University in China, a 3000bed tertiary care hospital. Between January 2009 and
December 2012, a total of 666 episodes of Enterobacter
cloacae were collected, and 64 (9.6%) isolates were
resistant to at least 1 carbapenem (imipenem MIC ≥2 µg/
mL, ertapenem MIC ≥1 µg/mL). We only studied the first
strain if more than one strain was collected in a patient.
Annual numbers and proportions of CREC are shown in
Table 1.
The CREC isolates were isolated from the bloodstream
(22 isolates), sputum (17 isolates), urine (10 isolates),
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Table 1. Annual numbers and proportions of CREC.
Strain (n)

2009

2010

2011

2012

Total E. cloacae

72

113

196

285

CREC

2 (2.8%)

5 (4.4%)

11 (5.6%)

46 (16.1%)

wound discharge (7 isolates), catheters (3 isolates),
abdominal fluid (3 isolates), pleural fluid (1 isolate),
and bile (1 isolate). The department distribution of the
CREC isolates were as follows: intensive care units (ICUs;
32 patients), respiratory wards (9 patients), urology
(7 patients), general surgery (3 patients), nephrology
(3 patients), endocrinology (2 patients), cardiology (2
patients), neurology (2 patients), orthopedic surgery (2
patients), and neurosurgery (2 patients).
A case-control study was performed to define the risk
factors associated with carbapenem-resistant Enterobacter
cloacae. The 64 CREC patients were considered as the
case group. The control group (patients infected by
carbapenem-susceptible Enterobacter cloacae) included
2 controls per case patient according to treatment date,
infection site, and the unit where the patient was treated.
The parameters reviewed included age, sex, underlying
diseases (diabetes mellitus, malignancy, gastrointestinal
tract disease, cardiovascular disease, genitourinary tract
disease, chronic pulmonary disease, chronic renal failure,
liver disease, cerebrovascular disease, intraabdominal
infection), prior antibiotic therapy (the use of antibiotics
[quinolones, cefazolins, or/and aminoglycosides] for
at least 2 weeks before a CREC culture result), recent
surgery during the past 30 days, and exposure to invasive
interventions (intravascular catheter, urinary catheter,
mechanical ventilation, nasogastric tube, and parenteral
nutrition) within 7 days before a CREC culture result.
2.2. Statistical analysis
Statistical analyses were performed using SPSS 15.0
(Chicago, IL, USA). Continuous variables were compared
with Student’s t-test. Categorical variables were compared
by a chi-square test or Fisher’s exact test. A P-value of less
than 0.05 was considered to be significant.
2.3. Microbiological studies
Identification and antimicrobial susceptibility testing
of the 666 Enterobacter cloacae strains were performed
using a VITEK-2 compact automatic system (bioMerieux,
France) according to the manufacturer’s instructions. The
strains identified with imipenem MIC of ≥2 µg/mL and/
or ertapenem MIC of ≥1 µg/mL by instrumental method
were screened as possible CREC and were confirmed
by an Etest (AB Biodisk, Sweden). The disc diffusion
method was performed to determine resistance to some
antimicrobial drugs (Table 2). The interpretative criteria
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for antimicrobial susceptibility testing were set according
to the Clinical Laboratory Standards Institute (CLSI) (8).
Pseudomonas aeruginosa ATCC 27853, Escherichia coli
ATCC 25922, E. coli ATCC 35218, K. pneumoniae ATCC
700603, and Enterococcus faecalis ATCC 29212 were used
for quality control of susceptibility tests.
2.4 Molecular analysis
Detection of ESBL genes (including blaSHV, blaTEM,
blaCTX-M-1, blaCTX-M-2, and blaCTX-M-9) and
carbapenemase genes (including blaKPC, blaIMP,
blaNDM-1, and blaVIM) was performed using polymerase
chain reaction (PCR). Template DNA was extracted by
the boiling preparation method (9). The primers used for
PCR are described in Table 3. The PCR parameters were
as follows: initial denaturation step at 94 °C for 5 min
followed by 35 cycles of denaturation at 94 °C for 30 s,
annealing at 40–56 °C for 30 s, and extension at 72 °C for
40 s, with a final extension step at 72 °C for 5 min. The PCR
products were examined by electrophoresis in 1% agarose
gels under UV light, purified and sequenced by Invitrogen
(Invitrogen, Shanghai, China), and compared with known
sequences available in the GenBank databases.
Pulsed-field gel electrophoresis (PFGE) of genomic
DNA was carried out with a CHEF Mapper XA apparatus
(Bio-Rad Laboratories, USA) to investigate the genetic
relatedness among the CREC isolates. Genomic DNA was
digested with XbaI (Takara Bio Inc., Japan). Electrophoresis
conditions were as follows: 19 h at 6 V/cm and 14 °C with
pulse times ranging from 2.2 to 54.2 s. PFGE patterns
were interpreted according to the criteria determined by
Tenover et al. (10).
3. Results
3.1. Clinical characteristics of the CREC isolates
During the study period, 666 isolates of Enterobacter
cloacae were identified at the study hospital. Of these, 64
(9.6%) isolates were defined as CREC. As shown in Table
1, the total number of Enterobacter cloacae and CREC both
presented growth trends during the 4 years. The prevalence
of CREC increased from 2.8% in 2009 to 16.1% in 2012,
and there was statistical significance between 2012 and the
other years (P < 0.01). The 64 CREC were mainly from the
bloodstream (22; 34.4%) and less frequently from other
samples, such as sputum (17; 26.6%), urine (10; 15.6%),
and wound discharge (7; 10.9%). Concerning the in-
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Table 2. Antibiotic susceptibility patterns of CREC.
Antibiotics

Sensitive N (%)

Intermediate N (%)

Resistance N (%)

Imipenem

0 (0)

6 (9.4)

58 (90.6)

Meropenem

0 (0)

6 (9.4)

58 (90.6)

Ertapenem

0 (0)

0 (0)

64 (100)

Ampicillin-sulbactam

0 (0)

0 (0)

64 (100)

Piperacillin-tazobactam

0 (0)

0 (0)

64 (100)

Ceftazidime

0 (0)

0 (0)

64 (100)

Ceftriaxone

0 (0)

0 (0)

64 (100)

Cefepime

0 (0)

0 (0)

64 (100)

Aztreonam

0 (0)

0 (0)

64 (100)

Levofloxacin

24 (37.5)

4 (6.3)

36 (56.3)

Ciprofloxacin

22 (34.4)

1 (1.6)

41 (64.1)

Amikacin

40 (62.5)

0 (0)

24 (37.5)

Tobramycin

7 (10.9)

0 (0)

57 (89.1)

Gentamicin

9 (14.1)

0 (0)

55 (85.9)

Trimethoprim-sulfamethoxazole

11 (17.2)

2 (3.1)

51 (79.7)

Tigecycline

50 (78.1)

5 (7.8)

9 (14.1)

Polymyxin B

60 (93.8)

0 (0)

4 (6.3)

Table 3. Primers used in this study.
Primer (5′—3′)
Forward

Reverse

Product length
(bp)

CTX-M -1

GGTTAAAAAATCACTGCGTC

TTGGTGACGATTTTAGCCGC

863

(13)

CTX-M -2

ATGATGACTCAGAGCATTCG

TGGGTTACGATTTTCGCCGC

865

(13)

CTX-M -9

ATGGTGACAAAGAGAGTGCA

CCCTTCGGCGATGATTCTC

869

(13)

SHV

CGCCGGGTTATTCTTATTTGTCGC

CGCCGGGTTATTCTTATTTGTCGC

795

(13)

TEM

ATAAAATTCTTGAAGACGAAA

GACAGTTACCAATGCTTAATCA

1079

(13)

KPC

ATGTCACTGTATCGCCGTCT

TTTTCAGAGCCTTACTGCCC

892

(14)

IMP

CATGGTTTGGTGGTTCTTGT

ATAATTTGGCGGACTTTGGC

488

(14)

I: CAGCACACT TCCTATCTC

I: CCGCAACCATCCCCTCTT

292

(14)

II: GGCGGAATGGCTCATCACGA

II: CGCAACACAGCCTGACTTTC

287

(14)

TTATGGAGCAGCAACGATGT

CAAAAGTCCCGCTCCAACGA

920

(14)

Amplicon

NDM-1
VIM

Reference
or source
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hospital distribution, the majority of these CREC patients
were from the ICU (32; 50.0%), followed by respiratory
wards (9; 14.1%), and urology (7; 10.9%).
3.2. Risk factors associated with CREC patients
There were no significant differences in demographic
characteristics and most clinical illnesses between the
cases and controls (P > 0.05). A univariate analysis showed
that CREC infections were associated with cerebrovascular
disease, prior treatment with antibiotics, intravascular
catheterization, urinary catheterization, mechanical
ventilation, and parenteral nutrition while the control
group was associated with chronic pulmonary disease (P
< 0.05) ( Table 4).
3.3. Antimicrobial susceptibility
A total of 64 CREC isolates were defined as multidrugresistant strains because of resistance to 3 or more classes
of antimicrobial agents. With the exception of 6 (9.4%)
isolates that had intermediate susceptibility to imipenem
and meropenem, all of the isolates were resistant to
carbapenems. All of the isolates were resistant to the
third- and fourth-generation cephalosporins, beta-lactam/

beta-lactamase inhibitor combinations, and aztreonam.
Fifty-seven (89.1%) isolates were resistant to tobramycin,
55 (85.9%) to gentamicin, 51 (79.7%) to trimethoprimsulfamethoxazole, 41 (64.1%) to ciprofloxacin, 36 (56.3%)
to levofloxacin, 24 (37.5%) to amikacin, 9 (14.1%) to
tigecycline, and 4 (6.3%) to polymyxin B (Table 2).
3.4. PCR assay analysis
A total of 49 (76.6%) isolates carried carbapenemase genes.
Only 2 families of carbapenemase genes were found in this
study, blaKPC and blaIMP. Thirty-eight (59.4%) isolates
had blaKPC-2 genes, 8 (12.5%) had blaIMP-8 genes, and 3
(4.7%) had blaIMP-1 genes. We did not find blaNDM-1 or
blaVIM genes in this study. A total of 39 (60.9%) isolates
possessed ESBL genes, among which 23 (35.9%) were
blaSHV-12 genes, followed by 8 (12.5%) with blaCTX-M-9
and 7 (10.9%) with blaTEM-1 genes. Only 1 (1.6%) of
isolates carried both blaSHV-12 and blaCTX-M-9.
Nineteen (29.7%) isolates produced single
carbapenemases, and 9 (14.1%) isolates produced
single ESBLs. Thirty (46.9%) isolates produced both
carbapenemases and ESBLs. Six (9.4%) isolates produced
neither carbapenemases nor ESBLs (Table 5).

Table 4. Comparisons of demographic data and clinical characters of 64 CREC patients.
Parameter

Cases (n = 64), n (%)

Controls (n = 128), n (%)

OR (95% CI)

P-value

Mean age, years (range)

59 (21–85)

65 (26–79)

11.44

0.38

No. (%) of males

34 (53.1)

56 (43.8)

1.46

0.220

Diabetes mellitus

4 (6.3)

17 (13.3)

0.44

0.141

Malignancy

6 (9.4)

9 (7.0)

1.37

0.568

Gastrointestinal tract disease

2 (3.1)

10 (7.8)

0.38

0.206

Cardiovascular disease

12 (18.8)

20 (15.6)

1.25

0.584

Genitourinary tract disease

3 (4.7)

12 (9.4)

0.48

0.254

Chronic pulmonary disease

5 (7.8)

28 (21.9)

0.30

0.015

Chronic renal failure

4 (6.3)

5 (3.9)

1.64

0.469

Liver disease

4 (6.3)

6 (4.7)

1.36

0.646

Cerebrovascular disease

24 (37.5)

18 (14.1)

3.67

<0.001

Intraabdominal infection

0 (0)

3 (2.3)

——

0.217

Prior treatment with antibiotics (≥2 weeks)

64 (100.0)

104 (81.3)

——

<0.001

Recent surgery

5 (7.8)

12 (9.4)

0.82

0.719

Intravascular catheter

16 (25.0)

8 (6.3)

5

<0.001

Urinary catheter

56 (87.5)

16 (12.5)

49

<0.001

Mechanical ventilation

10 (15.6)

1 (0.8)

11.88

<0.001

Nasogastric tube

1 (1.6)

1 (0.8)

——

>0.05

Parenteral nutrition

2 (3.1)

0 (0)

——

<0.05
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Table 5. Molecular characteristics of 64 CREC strains.
Beta-lactamase

No.

Genes (n)
SHV-12 (23)

ESBLs

TEM-1 (7)

39

CTX-M-9 (8)
SHV-12+CTX-M-9 (1)
KPC-2 (38)

Carbapenemase

IMP-1 (3)

49

IMP-8 (8)
Single ESBLs

9

SHV-12 (5), CTX-M-9 (1), TEM-1 (2), SHV-12+CTX-M-9 (1)

Single carbapenemases

19

KPC-2 (18), IMP-8 (1)

ESBLs and carbapenemases

30

SHV-12 + KPC-2 (10), TEM-1 + KPC-2 (4), SHV-12 + IMP-8 (6), SHV-12 + IMP-1
(2), CTX-M-9 + KPC-2 (6), CTX-M-9 + IMP-8 (1), TEM-1 + IMP-1 (1)

No ESBLs or carbapenemases

6

3.5. PFGE analysis
The genetic relatedness of the CREC isolates was
investigated by PFGE in our study. Lanes 3, 5, and 10
represented the same clone. All of the other isolates
yielded different DNA band profiles, and no obvious clonal
association was observed among them (Figure).
1

2

3

4

5

6

7

8

9

10

M

kb

1135
453
398.4
336
244
216
173
138.9
104
78.2
55
33

Figure. PFGE patterns of genomic DNAs of CREC. Lanes 3, 5,
and 10 present the same profile. Lanes 1, 2, 4, and 6–9: unrelated
isolates of CREC. Lane M: molecular weight marker (PFGE
marker, Salmonella ser. Braenderup HB9812).

4. Discussion
Carbapenems are traditionally considered to be the
last defense against serious infections caused by ESBLproducing Enterobacteriaceae. However, in recent years,
CREC has been detected in several countries (11–13). In
the last 4 years, the numbers of CREC increased year by
year. In 2012, 46 (16.1%) patients were diagnosed with
CREC infections in our hospital, about 3 times that of
the previous year (Table 1). According to PFGE results,
significant clonal spread was not observed among most of
them, showing that no outbreak of CREC happened during
these 4 years. The increase of CREC may be associated
with the intensive use of antibiotics, mutation of resistance
genes, and horizontal transfer of resistance genes (14,15).
This finding suggests that effective measures should be
taken to control the emergence and dissemination of CREC
strains in health care organizations and communities.
Evaluation of the risk factors for CREC infections
demonstrated that invasive interventions were significantly
associated with the CREC group (P < 0.05). This is likely due
to the fact that invasive therapy can increase the chances
of CREC infection and prolong the use of antibiotics.
This result is similar to those of previous studies (16–18).
These findings suggest that prompt discontinuation of
invasive interventions is an effective way to reduce the
risk of CREC infections. The use of antibiotics, especially
cephalosporins and carbapenems, was also a risk factor for
CREC infection. It is worrisome that cephalosporins and
carbapenems are frequently used to treat gram-negative
Bacillus infections in hospitals and community settings.
Empirical therapy with cephalosporins or carbapenems
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may lead to the emergence of carbapenem-resistant strains
(14,15). It is very important to choose suitable antibiotics
according to drug sensitivity tests and avoid the abuse
of antibiotics. In terms of disease prevalence, we found
that cerebrovascular disease was more common in the
case group, and chronic pulmonary disease was more
prevalent in the control group (P < 0.05). Unfortunately,
there is no additional research to determine whether
there is a connection between the diseases in this study. In
addition, we found that 50% of CREC patients came from
ICU wards. The ICU is a special department, and most
ICU patients have serious diseases, more opportunities
for invasive treatment, and longer courses of antibiotic
treatment; therefore, the ICU is another risk factor for
CREC infections.
In our study, 49 (76.6%) of CREC had carbapenemase
genes, and KPC-2 was the most common carbapenemase
type in the study hospital. Similar studies have been
reported in different counties and different regions of
China (19–21). Different results were also reported in
Chongqing in China. In another study, IMP and OXA
were the most prevalent carbapenemases, and KPC-2 was
not detected in their hospital (9).
Ten years ago, ESBLs were mainly produced by
Klebsiella pneumoniae and Escherichia coli. Now ESBLproducing Enterobacter cloacae have been reported in
many countries (22–24). This study found that 39 (60.9%)
CREC isolates produced ESBLs, which was higher than
that of noncarbapenem-resistant Enterobacter cloacae
(22,23). ESBL genes have been classified into 9 families
based on their amino acid sequences (25). TEM, SHV, and
CTX-M are the most common families. In this study, SHV12 (35.9%) was the main type and CTX-M was second
(12.5%). Yang et al. (1) reported that SHV-12 accounted
for 75.5% in ertapenem-resistant Enterobacter cloacae in
Taiwan. Xia et al. (9) reported that CTX-M was the most
common genotype (50.0%) in CREC in Chongqing in
China. These results indicate that the genotype distribution
of CREC is remarkably different in different countries and
regions.
The resistance mechanisms of carbapenems are
very complex and can be mediated by several means: 1)
carbapenemase production, 2) production of ESBLs or
AmpC β-lactamases associated with alterations in outer
membrane proteins, and 3) hyperexpression of efflux
systems (26–28). Carbapenemase production is the
most important carbapenem resistance mechanism in
Enterobacteriaceae. In this study, 6 CREC isolates were
not found to contain carbapenemase or ESBL genes,
implying that resistance may involve other mechanisms
not investigated in our study, such as production of other
β-lactamases or hyperexpression of efflux systems.
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Antimicrobial susceptibility testing showed that the
CREC isolates all exhibited multidrug resistance. All isolates
were either resistant or had intermediate susceptibility
to beta-lactams, including carbapenems. Some isolates
were only susceptible to aminoglycosides, quinolones,
trimethoprim-sulfamethoxazole,
tigecycline,
and
polymyxin. Current reports showed that only a minority
of antibacterial drugs, such as tigecycline and polymyxin,
can be first-line agents for treating carbapenem-resistant
Enterobacteriaceae infections (29). This finding indicates
that the options for treating the infections caused by CREC
are extremely limited. ESBLs and carbapenemases genes
are commonly located on plasmids or other mobile genetic
elements, which may harbor other antibiotic resistant
genes, such as quinolones and aminoglycosides. These
resistant genes can spread among bacteria together and
then contribute to multiresistant phenotypes of CREC.
PFGE studies demonstrated that 3 isolates exhibited
the same profile. They were all collected from the ICU
department within 2 months and had the same drugresistant gene profile (SHV-12 + KPC-2) and antimicrobial
susceptibility results, showing a possible clonal
dissemination of 1 isolate. This finding demonstrated
the potential epidemic threat of CREC in hospitals. The
other isolates exhibited distinct PFGE profiles, indicating
no obvious clonal association within them. It indicated
that the infections caused by CREC were spontaneous in
our hospital within the last 4 years. However, outbreaks
of carbapenemase-producing Enterobacteriaceae have
been reported in some hospitals (30). Due to the fact
that the infections with CREC are very difficult to treat
and associated with high morbidity and mortality, it is
necessary to monitor the emergence and spread of CREC
strains.
There are at least 3 limitations of our study. First, we
just selected a few common carbapenemase and ESBL
enzymes to analyze. Some other types, such as GES, SME,
and OXA, which were not detected in this study, might
exist in these CREC isolates. Second, we did not detect loss
of outer membrane proteins and efflux pump expression
in these isolates, which may be involved in carbapenem
resistance mechanisms. In addition, the number of CREC
isolates was small, and further investigation should be
done to verify the characteristics of CREC.
In summary, the infection rate of CREC has
increased in recent years. Over 60% of CREC isolates
had carbapenemase and/or ESBLs genes, and blaSHV-12
and blaKPC-2 were highly prevalent among them. Strict
measures should be taken to control the spread of these
pathogens in hospitals.
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